Publications

Real-world ALK testing compliance to NCCN guideline and factors of underutilization →

Bernicker, E, Xiao, Y, Abraham, A, Engstrom-Melnyk, J, Croix, D, Yang, B, Shah, RA, Madala, J, Allen, T

May 2020

Abstract

ASCO Annual Meeting

Use of prophylactic cranial irradiation in patients with extensive-stage small cell lung cancer receiving immunotherapy →

Yang, DX, Jairam, V, Park, HS, Decker, RH, Chiang, AC, Gross, CP, Yu, JB

May 2020

Abstract

ASCO Annual Meeting

PD-1 targeted immunotherapy for advanced hepatocellular cancer: current utilization and outcomes in the United States →

Uhlig, J, Stein, S, Kim, HS

May 2020

Abstract

ASCO Annual Meeting

Real-world outcomes of patients with BRAF-mutated mCRC treated in the United States →

Braithwaite, M, Nevala-Plagemann, C, Baron, K, Halland, B, Garrido-Laguna, I, Pappas, LM, Moser, JC

May 2020

Abstract

ASCO Annual Meeting

Comparative effectiveness of second-line single-agent atezolizumab, nivolumab, and pembrolizumab in patients with locally advanced or metastatic urothelial cancer who progressed on platinum-based systemic chemotherapy: results from a real-world dataset →

Swami, U, Halland, B, Maughan, BL, Nussenzveig, S, Esther, J, Kessel, A, Pal, SK, Grivas, P, Agarwal, N

May 2020

Abstract

ASCO Annual Meeting

Real-world outcomes after second-line treatment in non-small cell lung cancer patients treated with immunotherapy →

Marmarelis, ME, Hwang, W-T, Yang, Y-X, Ciunci, C, Singh, A, Aggarwal, C, Cohen, RB, Langer, CJ, Mamtani, R, Bauml, JM

May 2020

Abstract

ASCO Annual Meeting

Prevalence of ALK mutation in advanced NSCLC patients in the United States →

Allen, T, Xiao, Y, Abraham, A, Redpath, S, Engstrom-Melnyk, J, Croix, D, Yang, B, Shah, RA, Madala, J, Bernicker, E

May 2020

Abstract

ASCO Annual Meeting

Uptake of targeted therapy in clinical practice among US patients with ovarian cancer →

Chan, J, Meyer, L, Luhn, P, Flores, C, Bastere-Truchot, L, Downer, MK, Lin, YG, Wright, JD

May 2020

Abstract

ASCO Annual Meeting

Patient characteristics and treatment patterns in relapsed/refractory multiple myeloma patients after exposure to a proteasome inhibitor, an immunomodulatory agent, and daratumumab →

Mehra, M, Vogel, M, Valluri, S, Nair, S, Schecter, J, Jagannath, S, Weisel, K, Usmani, SZ

May 2020

Abstract

ASCO Annual Meeting

Racial disparities in utilization and effectiveness of first-line therapies in metastatic castrate-resistant prostate cancer →

Marar, M, Mamtani, R, Narayan, V, Parikh, RB

May 2020

Abstract

ASCO Annual Meeting

Trends in real-world clinical outcomes among patients with metastatic pancreatic adenocarcinoma treated with liposomal irinotecan based regimens in the United States →

Koeller, J, Cockrum, P, Belanger, B, Corvino, FA, Surinach, A, Kim, GP

May 2020

Abstract

ASCO Annual Meeting

Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: a contemporary clinical practice patterns study →

Gondos, A, Paz-Ares, L, Saldana, D, Thomas, M, Mascaux, C, Bubendorf, L, Barlesi, F

May 2020

Abstract

ASCO Annual Meeting

Role of real-world evidence for oncology product registration in the United States: a review of approvals by the U.S. Food and Drug Administration from 2015 to 2019 →

Arondekar, B, Bhak, R, Dersarkissian, M, Huynh, L, Wang, K, Davis, E, Wonrson, B, Duh, MS

May 2020

Abstract

ASCO Annual Meeting

12-month uptake of PD-L1 testing and atezolizumab + nab-paclitaxel treatment in metastatic triple-negative breast cancer following accelerated FDA-approval in the United States →

Emens, LA, Craggs, C, Debiasi, M, Kent, M, Luhn, P, Hamilton, EP

May 2020

Abstract

ASCO Annual Meeting

Clinical outcomes between patients with and without RET fusions in advanced/metastatic non-small cell lung cancer in the United States →

Sireci, A, Hess, LM, Han, Y, Zhu, YE, Bhandari, NR, Martinez, R

May 2020

Abstract

ASCO Annual Meeting

Indirect comparison of TAK-788 vs real-world data outcomes in refractory non-small cell lung cancer with EGFR exon 20 insertions →

Horn, L, Lin, HM, Padda, SK, Aggarwal, C, McCoach, CE, Zhu, Y, Yin, Y, Li, S, Feng, Z, Neal, JW

May 2020

Abstract

ASCO Annual Meeting

Real-world use of liposomal irinotecan-based regimens among patients with metastatic pancreatic adenocarcinoma in the United States →

Kim, GP, Cockrum, P, Surinach, A, Koeller, J

May 2020

Abstract

ASCO Annual Meeting

Real-world treatment patterns and clinical outcomes of advanced melanoma patients following disease progression on anti-PD-1-based therapy →

Hernandez-Aya, LF, Burke, M, Collins, JM, Earle, D, Hamilton, M, Nordstrom, BL, Zhang, Y, Srivastava, S

May 2020

Abstract

ASCO Annual Meeting

Uptake of first-line immune checkpoint inhibitors among medically frail patients with advanced solid malignancies →

Parikh, RB, Cohen, RB, Min, EJ, Wileyto, EP, Riaz, F, Gross, CP, Long, Q, Mamtani, R

May 2020

Abstract

ASCO Annual Meeting

Real-world dosing, management, and clinical outcomes of patients with metastatic pancreatic adenocarcinoma treated with liposomal irinotecan →

Abushahin, LI, Cockrum, P, Surinach, A, Belanger, B

May 2020

Abstract

ASCO Annual Meeting

Real-world outcomes among patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in first-line setting →

Simmons, D, Dersarkissian, M, Shenolikar, R, Wang, M-J, Lax, A, Muthukumar, A, Laliberté, F, Duh, MS

May 2020

Abstract

ASCO Annual Meeting

Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent epithelial ovarian cancer: are some patients missing out? →

Moss, H, Secord, AA, Perhanidis, J, Hawkes, C

May 2020

Abstract

ASCO Annual Meeting

Real-world patterns of molecular testing in advanced melanoma: adherence to guidelines →

Olszanski, AJ, Farma, JM

May 2020

Abstract

ASCO Annual Meeting

Overall survival in Non-small cell lung cancer patients with comorbidities treated with frontline chemotherapy or immunotherapy: a real-world data collaboration →

Rivera, DR, Lasiter, L, Christian, JB, Enewold, L, Espirito, JL, Hansen, E, Henk, HJ, Kushi, L, Lane, D, Natanzon, Y, Benito, RP, Rasmussen, E, Robert, NJ, Stewart, M, Sweetnam, C, Tymejczyk, O, Valice, E, Wagner, J, Zander, A, Allen, J

May 2020

Abstract

ASCO Annual Meeting

Flatiron-authored

Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer →

Shore, ND, Higano, CS, George, DJ, Sternberg, CN, Saad, F, Tombal, B, Miller, K, Kalinovsky, J, Jiao, X, Tangirala, K, Sartor, AO

May 2020

Manuscript

Prostate Cancer and Prostatic Diseases

Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer →

Bartlett, CH, Mardekian, J, Cotter, MJ, Huang, X, Zhang, Z, Parrinello, CM, Bourla, AB

April 2020

Manuscript

PLoS One

Flatiron-authored

STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort →

Papillon-Cavanagh, S, Doshi, P, Dobrin, R, Szustakowski, J, Walsh, AM

April 2020

Manuscript

ESMO Open

Real-world outcomes for advanced non-small cell lung cancer patients treated with a PD-(L)1 inhibitor beyond progression →

Stinchcombe, TE, Miksad, RA, Gossai, A, Griffith, SD, Torres, AZ

April 2020

Manuscript

Clinical Lung Cancer

Flatiron-authored

Primary tumor location and survival in colorectal cancer: A retrospective cohort study →

Aggarwal, H, Sheffield, KM, Li, L, Lenis, D, Sorg, RA, Barzi, A, Miksad, RA

April 2020

Manuscript

World Journal of Gastrointestinal Oncology

Flatiron-authored

Impact of delaying initiation of anaplastic lymphoma kinase inhibitor treatment on survival in patients with advanced non-small-cell lung cancer →

Sheinson, D, Wong, WB, Wu, N, Mansfield, AS

April 2020

Manuscript

Lung Cancer

Letting the GENIE out of its bottle: examining the potential of real-world clinico-genomic data →

Castellanos, EH, Baxi, SS

April 2020

Manuscript

Cancer Discovery

Flatiron-authored

Impact of previous local treatment for prostate cancer on subsequent metastatic disease: Comparative analysis and survival outcome

Shahait, M, Alshannaq, H, Dobbs, RW, Kim, J, Narayan, V, Lee, DI

April 2020

Abstract

American Urological Association Annual Meeting

Patterns and adoption of BRCA testing in ovarian cancer in the real world: observations from Flatiron Health →

Meyer, L, Wright, JD, Downer, MK, Incerti, D, Luhn, P, Dolades, I, Bastiere-Truchot, L, Lin-Liu, Y, Chan, JK

March 2020

Abstract

Society of Gynecologic Oncology Annual Meeting

Implementing an electronic end-of-life chemotherapy utilization measure →

Kraut, J, Mooney, K, Sweetenham, JW, Page, RD, Adelson, KB, Agarwala, V, Fessele, KL, Hamrick, HJ, Kaganman, I, Martineau, J, Abernethy, AP, Meropol, NJ

March 2020

Manuscript

Journal of Oncology Practice

Flatiron-authored

Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR →

Ma, X, Long, L, Moon, S, Adamson, BJS, Baxi, SS

March 2020

Manuscript

medRxiv

Flatiron-authored

Quality measurement in cancer care: A review and endorsement of high-impact measures and concepts →

D'Amico, TA, Bandini, L, Balch, A, Benson III, AI, Edge, SB, Fitzgerald, L, Green, RJ, Koh, W, Kolodziej, MA, Kumar, S, Meropol, NJ, Mohler, JL, Pfister, D, Walters, RS, Carlson, RW

March 2020

Manuscript

JNCCN

Flatiron-authored

Real-world treatment patterns and time on treatment (rwToT) in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) with disease progression on or after platinum-containing chemotherapy in United States (U.S.) →

Chirovsky, D, Zhiwen, L, Yu, F, Baxi, SS, Chandwani, S, Joo, S, Ramakrishnan, K

February 2020

Abstract

Multidisciplinary Head and Neck Cancers Symposium

Flatiron-authored

Real-world outcomes in patients with locally advanced or metastatic urothelial carcinoma receiving taxane monotherapy following platinum and anti-PD-1/L1 therapy →

Hepp, Z, Shah, S, Tan, K, Balakrishna, S

February 2020

Abstract

ASCO GU Symposium

Flatiron-authored

Author’s response to ‘‘A Letter in Support of Real-World RECIST’’ →

Griffith, SD, Tucker, MG, Bowser, B, Calkins, G, Chang, C, Guardino, E, Khozin, S, Kraut, J, You, P, Schrag, D, Miksad, RA

February 2020

Manuscript

Advances in Therapy

Flatiron-authored

Real-world dosing patterns and outcomes of patients with metastatic pancreatic cancer treated with a liposomal irinotecan regimen in the United States →

Barzi, A, Miksad, RA, Surinach, A, Corvino, FA, Wang, S, Torres, AZ, Mamlouk, K, Pulgar, S, Valderrama, A, Bekaii-Saab, T, Ahn, D

January 2020

Manuscript

Pancreas

Flatiron-authored

Assessing real-world biomarker testing rates in metastatic colon cancer →

Nakhoda, S, Deng, M, Iyer, P, Handorf, E, Jain, R, Meropol, NJ, Dotan, E

January 2020

Abstract

ASCO GI Symposium

Flatiron-authored

Impact of dose reductions on clinical outcomes among patients (pts) with metastatic pancreatic cancer (mPC) treated with liposomal irinotecan (nal-IRI) in oncology clinics in the United States →

Cockrum, P, Surinach, A, Kim, GP, Mercer, D, Koeller, J, Miksad, RA

January 2020

Abstract

ASCO GI Symposium

Flatiron-authored

Survival outcomes based on sequence of therapy using FOLFIRINOX and nabpaclitaxel + gemcitabine in metastatic pancreatic ductal adenocarcinoma →

Baron, K, Nevala-Plagemann, C, Moser, JC, Halland, B, Wang, X, Garrido-Laguna, I

January 2020

Abstract

ASCO GI Symposium

Gemcitabine and nab-paclitaxel in older adults with metastatic pancreatic cancer: are two doses per cycle enough? →

Winer, A, Handorf, E, Dotan, E

January 2020

Abstract

ASCO GI Symposium

Real-world treatment patterns and survival in patients (pts) with hepatocellular carcinoma in the United States →

Morse, M, Meyer, A-M, Lawrance, M, Pereira, M, Mhatre, SK, Gaillard, V, Dayyani, F

January 2020

Abstract

ASCO GI Symposium

Real-world patterns of care among patients with metastatic pancreatic cancer (mPC) →

O'Reilly, EM, Surinach, A, Wu, Z, Cockrum, P

January 2020

Abstract

ASCO GI Symposium

Impact of prior irinotecan exposure on outcomes of metastatic pancreatic cancer (mPC) patients →

O'Reilly, EM, Surinach, A, Dillon, A, Cockrum, P, Yu, KH

January 2020

Abstract

ASCO GI Symposium

Real-world rates of hematology lab abnormalities and associated cost among metastatic pancreatic cancer (mPC) therapeutic regimens →

Dieguez, G, Surinach, A, Mercer, D, Cockrum, P, Kim, GP, Pelizzari, P

January 2020

Abstract

ASCO GI Symposium

Association of real-world agreement between HER2 expression and ERBB2 amplification with trastuzumab therapy benefit in advanced gastric/esophageal (adv GE) cancer patients (pts) →

Stein, S, Snider, J, McCusker, M, Miksad, RA, Alexander, BM, Castellanos, EH, Backenroth, D, Schrock, AB, Madison, R, Carson, KR, Ali, SM

January 2020

Abstract

ASCO GI Symposium

Flatiron-authored

Real-world outcomes of first-line U.S. patients with unresectable advanced or metastatic gastroesophageal adenocarcinoma by primary tumor location →

Shankaran, V, Xiao, H, Bertwistle, D, Zhang, Y, Abraham, P, Chau, I

January 2020

Abstract

ASCO GI Symposium